A Phase 3 interventional study of Placebo and Upadacitinib in Rheumatoid Arthritis, sponsored by AbbVie. Completed at 167 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 7 in phase 3, and was the 5th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–65
AbbVie
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 661 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 19 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 4th largest by enrollment of the 38 interventional ones that give a count, is one of 9 that started in 2015, is one of 11 in phase 3, and was the 51st registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, from their registry updates:
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid arthritis who were on a stable dose of csDMARDs and had an inadequate response to csDMARDs.
This Phase 3 multicenter study includes two periods. Period 1 is a 12-week, randomized, double-blind, parallel-group, placebo-controlled period designed to compare the safety and efficacy of upadacitinib 30 mg once daily and upadacitinib 15 mg once daily versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid arthritis (RA) who were on a stable dose of csDMARDs and had an inadequate response to csDMARDs.
Period 2 is a 248-week blinded long-term extension period to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 30 mg once daily and upadacitinib 15 mg once daily in participants who completed Period 1.
Participants were to be randomized in a 2:2:1:1 ratio using interactive response technology (IRT) to receive double-blind study drug in one of the following treatment groups:
Randomization was stratified by prior exposure to biological disease-modifying anti-rheumatic drug (bDMARD) (yes/no) and geographic region.
Following Protocol Amendment 6.0 approval in December 2019, all participants still on study received open-label upadacitinib 15 mg QD, including those on upadacitinib 30 mg QD, with the earliest switch occurring at the Week 168 visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants receive upadacitinib 15 mg once daily for 12 weeks. Period 2: Participants continue to receive upadacitinib 15 mg once daily for an additional 248 weeks.
Drug: Upadacitinib
Period 1: Participants receive upadacitinib 30 mg once daily for 12 weeks. Period 2: Participants continue to receive upadacitinib 30 mg once daily for an additional 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.
Drug: Upadacitinib
Period 1: Participants receive placebo once daily for 12 weeks. Period 2: Participants receive upadacitinib 15 mg once daily for 248 weeks.
Drug: Placebo · Drug: Upadacitinib
Period 1: Participants receive placebo once daily for 12 weeks. Period 2: Participants receive upadacitinib 30 mg once daily for 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.
Drug: Placebo · Drug: Upadacitinib
Tablet; Oral
Tablet; Oral
Also known as: ABT-494, Rinvoq
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.
Time frame: Week 12
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.
Time frame: Baseline and Week 12
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 12
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12
Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
Time frame: Week 12
Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12
Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.
Time frame: Week 12
Change From Baseline in Duration of Morning Stiffness at Week 12
Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.
Time frame: Baseline and Week 12
Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a five point Likert scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.
Time frame: Baseline and week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 1
Participants were randomized at 149 centers in 35 countries in North America, eastern and western Europe, Asia, South America, Australia, New Zealand, and South Africa. The study included a 12-week placebo-controlled, double-blind period (Period 1), and a 5-year (248-week) double-blind extension (Period 2).
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 110 | 111 | 221 | 219 |
| Received study drug | 110 | 111 | 221 | 219 |
| Completed | 104 | 104 | 213 | 201 |
| Not completed | 6 | 7 | 8 | 18 |
| Withdrew: Adverse event | 3 | 3 | 3 | 9 |
| Withdrew: Withdrawal by subject | 1 | 2 | 5 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 2 |
| Withdrew: Other | 2 | 1 | 0 | 2 |
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 103 | 103 | 212 | 200 |
| Received study drug | 103 | 102 | 207 | 199 |
| Switched to upadacitinib 15 mg after protocol amendment 6 | 0 | 53 | 0 | 126 |
| Completed | 61 | 49 | 130 | 120 |
| Not completed | 42 | 54 | 82 | 80 |
| Withdrew: Adverse event | 13 | 16 | 17 | 30 |
| Withdrew: Withdrawal by subject | 14 | 21 | 31 | 30 |
| Withdrew: Lost to follow-up | 5 | 5 | 10 | 4 |
| Withdrew: Coronavirus disease - 2019 (covid-19) infection | 1 | 0 | 0 | 1 |
| Withdrew: Covid-19 logistic restrictions | 1 | 0 | 1 | 0 |
| Withdrew: Other | 8 | 12 | 23 | 15 |
The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 35.7 (29.4 to 42.1) | 63.8 (57.5 to 70.1) | 66.2 (59.9 to 72.5) |
The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 17.2 (12.2 to 22.2) | 48.4 (41.8 to 55.0) | 47.9 (41.3 to 54.6) |
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.
| units on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12 | -1.02 (-1.22 to -0.82) | -2.20 (-2.40 to -2.00) | -2.34 (-2.54 to -2.14) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
| units on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | -0.25 (-0.34 to -0.17) | -0.59 (-0.67 to -0.51) | -0.54 (-0.62 to -0.46) |
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.
| units on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 12 | 3.03 (1.88 to 4.18) | 7.58 (6.43 to 8.74) | 8.01 (6.84 to 9.18) |
Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12 | 10.0 (6.0 to 13.9) | 30.8 (24.7 to 36.9) | 28.3 (22.3 to 34.3) |
Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12 | 19.0 (13.8 to 24.2) | 40.3 (33.8 to 46.7) | 42.0 (35.5 to 48.5) |
Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.
| minutes | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Duration of Morning Stiffness at Week 12 | -34.27 (-54.63 to -13.91) | -85.28 (-105.61 to -64.95) | -85.13 (-105.65 to -64.62) |
The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a five point Likert scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.
| units on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12 | 2.96 (1.62 to 4.30) | 7.91 (6.56 to 9.27) | 7.74 (6.38 to 9.11) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 14.9 (10.2 to 19.6) | 38.0 (31.6 to 44.4) | 43.4 (36.8 to 49.9) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 5.9 (2.8 to 9.0) | 20.8 (15.5 to 26.2) | 26.5 (20.6 to 32.3) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1 | 8.6 (4.9 to 12.3) | 22.2 (16.7 to 27.6) | 28.3 (22.3 to 34.3) |
Collected over Period 1: From first dose of study drug (placebo or upadacitinib) up to Week 12 or up to 30 days after last dose for participants who discontinued study drug prior to Week 12. Period 1+2: From first dose of upadacitinib up to 30 days after last dose (maximum of 264 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Placebo | 1/221 (0.5%) | 5/221 (2.3%) | 68/221 (30.8%) |
| Period 1: Upadacitinib 15 mg | 0/221 (0%) | 10/221 (4.5%) | 83/221 (37.6%) |
| Period 1: Upadacitinib 30 mg | 0/219 (0%) | 7/219 (3.2%) | 74/219 (33.8%) |
| Period 1+2: Upadacitinib 15 mg | 4/324 (1.2%) | 91/324 (28.1%) | 241/324 (74.4%) |
| Period1+2: Upadacitinib 30 mg | 7/321 (2.2%) | 102/321 (31.8%) | 233/321 (72.6%) |
| Period 2: Upadacitinib 15 mg After Switch | 2/179 (1.1%) | 19/179 (10.6%) | 51/179 (28.5%) |
| Event | Period 1: Placebo | Period 1: Upadacitinib 15 mg | Period 1: Upadacitinib 30 mg | Period 1+2: Upadacitinib 15 mg | Period1+2: Upadacitinib 30 mg | Period 2: Upadacitinib 15 mg After Switch |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/221 | 0/221 | 0/219 | 6/324 | 11/321 | 0/179 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/221 | 1/221 | 1/219 | 6/324 | 8/321 | 2/179 |
| COVID-19 pneumoniaInfections and infestations | 0/221 | 0/221 | 0/219 | 6/324 | 2/321 | 4/179 |
| Acute myocardial infarctionCardiac disorders | 0/221 | 0/221 | 0/219 | 1/324 | 5/321 | 0/179 |
| CholelithiasisHepatobiliary disorders | 0/221 | 0/221 | 0/219 | 1/324 | 4/321 | 0/179 |
| SepsisInfections and infestations | 0/221 | 0/221 | 0/219 | 1/324 | 4/321 | 0/179 |
| Atrial fibrillationCardiac disorders | 1/221 | 0/221 | 0/219 | 4/324 | 1/321 | 0/179 |
| PyrexiaGeneral disorders | 0/221 | 0/221 | 0/219 | 1/324 | 3/321 | 0/179 |
| Wound infection staphylococcalInfections and infestations | 0/221 | 0/221 | 1/219 | 0/324 | 3/321 | 0/179 |
| FallInjury, poisoning and procedural complications | 0/221 | 0/221 | 0/219 | 3/324 | 0/321 | 0/179 |
| Event | Period 1: Placebo | Period 1: Upadacitinib 15 mg | Period 1: Upadacitinib 30 mg | Period 1+2: Upadacitinib 15 mg | Period1+2: Upadacitinib 30 mg | Period 2: Upadacitinib 15 mg After Switch |
|---|---|---|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 9/221 | 12/221 | 12/219 | 64/324 | 57/321 | 4/179 |
| NASOPHARYNGITISInfections and infestations | 9/221 | 12/221 | 13/219 | 60/324 | 45/321 | 3/179 |
| URINARY TRACT INFECTIONInfections and infestations | 8/221 | 8/221 | 6/219 | 55/324 | 46/321 | 4/179 |
| HERPES ZOSTERInfections and infestations | 1/221 | 1/221 | 1/219 | 27/324 | 44/321 | 4/179 |
| BRONCHITISInfections and infestations | 5/221 | 4/221 | 5/219 | 35/324 | 42/321 | 2/179 |
| HYPERTENSIONVascular disorders | 4/221 | 3/221 | 2/219 | 41/324 | 27/321 | 4/179 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 5/221 | 1/221 | 5/219 | 36/324 | 33/321 | 2/179 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/221 | 5/221 | 7/219 | 36/324 | 32/321 | 1/179 |
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 10/221 | 4/221 | 4/219 | 36/324 | 30/321 | 8/179 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 6/221 | 2/221 | 3/219 | 33/324 | 25/321 | 3/179 |
The Full Analysis Set (FAS) includes all randomized participants who received at least one dose of study drug. The two placebo groups are combined for analysis of results in Period 1.
| Age, Continuous(years) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Mean | 56.0 ± 12.22 | 55.3 ± 11.47 | 55.8 ± 11.29 | 55.7 ± 11.65 |
| Age, Customized(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| < 40 years | 21 | 23 | 22 | 66 |
| 40 to 64 years | 145 | 153 | 145 | 443 |
| ≥ 65 years | 55 | 45 | 52 | 152 |
| Sex: Female, Male(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Female | 166 | 182 | 172 | 520 |
| Male | 55 | 39 | 47 | 141 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 27 | 23 | 30 | 80 |
| Not Hispanic or Latino | 194 | 198 | 189 | 581 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| White | 187 | 188 | 186 | 561 |
| Black or African American | 10 | 13 | 8 | 31 |
| American Indian / Alaskan Native | 1 | 0 | 1 | 2 |
| Asian | 19 | 19 | 21 | 59 |
| Multiple | 4 | 1 | 3 | 8 |
| Geographical Region(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| North America | 90 | 88 | 89 | 267 |
| South/Central America | 8 | 10 | 11 | 29 |
| Western Europe | 24 | 22 | 23 | 69 |
| Eastern Europe | 74 | 76 | 73 | 223 |
| Asia | 16 | 17 | 15 | 48 |
| Other | 9 | 8 | 8 | 25 |
| Prior Biological DMARD Use(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Yes | 29 | 27 | 28 | 84 |
| No | 192 | 194 | 191 | 577 |
| Duration of Rheumatoid Arthritis (RA) Diagnosis(years) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Mean | 7.2 ± 7.45 | 7.3 ± 7.89 | 7.3 ± 7.86 | 7.3 ± 7.72 |
9 further baseline measures are reported on the registry.
Showing the first 100 of 167 sites across 38 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · www.abbvie.com
Ran from Dec 2015 to primary completion in Apr 2017, 16 months.
Results were first posted in Oct 2019, 2 years 5 months after primary completion. A results delay was requested in Jan 2018.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 16 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib